| Mouse Metabolic Phenotyping Centers
(MMPC)
| The MMPC is a National Institutes of Health-sponsored resource that provides experimental testing services to scientists studying diabetes, obesity, diabetic complications, and other metabolic diseases in mice. |
| Acute Liver Failure Study Group
(ALFSG)
| The Acute Liver Failure Study Group is collecting biosamples and information on the natural history, causes and outcomes of Acute Liver Failure in the United States. In addition to the database, a clinical trial conducted to test whether the drug… |
| Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction
(EPISOD)
| The EPISOD study is a prospective, double-blind, randomized, sham-controlled, multi-center clinical trial. The EPISOD study enrolls subjects who have received a prior cholecystectomy and are diagnosed with the clinical syndrome of Sphincter of Oddi… |
| Integrated Islet Distribution Program
(IIDP)
| The goal of the Integrated Islet Distribution Program (IIDP) is to work with the leading islet isolation centers in the U.S. to distribute high quality human islets to the diabetes research community, in order to advance scientific discoveries and… |
| Inflammatory Bowel Disease Genetic Consortium
(IBDGC)
| The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) consists of investigators from seven sites in the U.S. and Canada, who have recruited a large sample of inflammatory bowel disease patients, their relatives, and control subjects. All… |
| Efficacy and Mechanisms of Glutamine Dipeptide in the Surgical Intensive Care Unit
(GLND)
| The GLND trial is a multi-center, double-blind, placebo-controlled, intent-to-treat Phase III trial, designed to determine the effect of parenteral glutamine (GLN) dipeptide on important clinical outcomes in patients requiring surgical intensive care… |
| Action to Control Cardiovascular Disease Risk in Diabetes Follow-up Study
(ACCORDION)
| ACCORDION (sponsored by NHLBI) is a prospective, observational follow-up study of at least 8000 participants who were treated and followed in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Treatment in ACCORD ended in 2009 and… |
| Action for Health in Diabetes
(Look AHEAD)
| Look AHEAD is a 16-center, randomized clinical trial investigating the long-term health effects of an intensive lifestyle intervention designed to produce weight loss. Look AHEAD enrolled 5,145 overweight or obese participants with type 2 diabetes… |
| Diabetic Complications Consortium
(DiaComp)
| The goal of the NIDDK-sponsored Diabetic Complications Consortium (DiaComp) is to foster communication and collaboration between investigator communities involved in complications research. Toward this goal, DiaComp: (1) sponsors annual meetings in… |
| Mutant Mouse: Kmt2d (lysine (K)-specific methyltransferase 2D) (MII4 LoxP Mouse) | Mll4-flox. Conditional knockout mice for the histone methyltransferase Mll4 (Kmt2d) will help understand its role as a tumor suppressor. Mono- and di-methylations on histone H3 lysine 4 (H3K4me1 and H3K4me2) are epigenetic marks for transcriptional… |
| Sphk2 KO Mouse
(Mutant Mouse: Sphk2 (Sphingosine Kinase 2))
| A knockout mouse for Sphingosine kinase 2 (Sphk2).
Sphingosine kinase 1 and 2 are enzymes that produce sphingosine-1-phosphate (S1P), a potent bioactive compound that activates a family of G-protein coupled receptors known as S1P receptors… |
| Gaucher Gba-444 knock-in(Gba tm2Rlp) Mouse
(Mutant Mouse: Gba (glucosidase, beta, acid).Knock-in P444L ±A456P mimic Gaucher disease.)
| Gba-444 knock-in mice carrying the milder L444P Gaucher disease mutation (Gba-L444P mice) and the severe Gaucher disease mutation (Gba-L444P A456P mice).
Gba-L444P and Gba-L444P A456P mice, respectively, carry common gene mutations for milder or… |
| S1pr1 KO (S1pr1 tm1Rlp) Mouse
(Mutant Mouse: S1pr1 (spingosine-1-phosphate receptor 1))
| A Sphingosine-1-phosphate Receptor-1 (S1pr1) knockout mouse
Sphingosine-1-phosphate (S1P) is a potent bioactive lipid that activates a family of G-protein coupled receptors, S1P1, S1P2, S1P3, S1P4 and S1P5. The S1P1 receptor is widely expressed and… |
| S1pr1 LoxP (S1pr1 tm2Rlp) Mouse
(Mutant Mouse: S1pr1)
| A conditional knockout mouse for S1pr1
Sphingosine-1-phosphate (S1P) is a potent bioactive lipid that activates a family of G-protein coupled receptors, S1P1, S1P2, S1P3, S1P4 and S1P5. The S1P1 receptor is widely expressed and has critical functions… |
| S1pr2 KO Mouse
(Mutant Mouse: S1pr2)
| A Spingosine-1-phosphate Receptor-2 (S1pr2) knockout mouse.
Sphingosine-1-phosphate (S1P), a sphingolipid metabolite, activates cell signaling by interacting with a family of G-protein-coupled cell-surface S1P receptors that activate different and… |
| S1pr3 KO Mouse
(Mutant Mouse: s1pr3)
| A Spingosine-1-phosphate Receptor-3 (S1pr3) knockout mouse.
Sphingosine-1-phosphate (S1P), a sphingolipid metabolite, activates cell signaling by interacting with a family of G-protein-coupled cell-surface S1P receptors that activate different and… |
| Mutant Mouse: Kdm6a (lysine (K)-specific demethylase 6A) (UTX Knockin Mouse) | UTX-KI. Enzyme-dead knockin (KI) mice for the histone demethylase UTX (Kdm6a) will help understand its role in tumor suppression and stem cell–mediated tissue regeneration. Di- and tri-methylations on histone H3 lysine 27 (H3K27me2 and H3K27me3) are… |
| Cryogenic MAS NMR Probe: Collaboration for Commercialization with Revolution NMR | A Nuclear Magnetic Resonance (NMR) probe is a device that inserts into the magnet of an NMR spectrometer and contains both the radio-frequency circuitry for NMR experiments and the sample of interest. Magic-angle Spinning (MAS) is a technique in… |
| M5 Muscarinic receptor KO (Chrm5 tm1Jwe) Mouse
(Mutant Mouse: Chrm5)
| M5 Muscarinic Receptor Knockout: Deficiency of M5Rs reduces drug-seeking behavior.
The five Muscarinic Acetylcholine (ACh) receptors are G-protein coupled receptors (M1R-M5R). M1R, M3R and M5R selectively couple to Gq/G11; M2R and M4R selectively… |
| MEN1, the gene associated with multiple endocrine neoplasia type 1, menin polypeptides and uses thereof (U.S. Patent Number 7,358,347) | The invention relates to the discovery of a novel tumor suppressor gene which is associated with multiple endocrine neoplasia type 1. The gene has been designated MEN1 and the gene product is menin. The absence of this protein and associated… |
| Use of homo sapiens chromosome 1 open reading frame 28 (c1orf28) in the diagnosis of hyperparathyroidism-jaw tumor syndrome (U.S. Patent Application Number WO 2003094860 A3) | The present invention provides an isolated or purified oligonucleotide consisting essentially of the nucleotide sequence of Clorf28 and comprising a mutation; a fragment of the oligonucleotide; a vector comprising the oligonucleotide or fragment… |
| Anti-HIV Acylthiol & Thioether prodrugs (U.S. Patent Number 12/414,321) | These inventions provide the compositions, pharmaceutical carrier, and usages of the new Acylthiols (E-329-2000 family) and Thioether pro-drug (E-177-2010 family) compounds in treatment of retroviral infections such as HIV. These compounds target the… |
| Programmable self-assembled nanostructures based on sidechain-modified pna for the multivalent display of ligands (U.S. Patent Number EP 2569328 A2) | The invention concerns compositions comprising strands of polynucleotide and strands of PNA, each PNA strand comprising:
- (i) from 2 to 50 nucleobase subunits and
- (ii) one or more gamma substituents.
The PNA strands are complementary to at least a… |
| A3 Adenosine Receptor Antagonists (U.S. Patent Number 6,376,521) | This invention relates to a method of decreasing intraocular pressure by administrating an A3 subtype adenosine receptor antagonist, a calmodulin antagonist or an antiestrogen such as tamoxifen. |
| Epibatidine and derivatives, compositions and methods of treating pain (Patent Number U.S. 5,314,899) | The present invention is directed to compounds, compositions and methods of treating pain, and derivatives that have potent analgetic activity. The compounds have the formula: ##STR1## wherein R.sup.1 is selected from H, lower alkyl, C.sub.3 -C.sub.9… |
| Nicotinic acetylcholine receptor agonists (U.S. Patent Application Number WO 2011116282 A3) | The invention provides novel nicotinic acetylcholine receptor agonists, for example, phaiitasmidine and derivatives thereof, for example a compound of formula (I). Also disclosed are methods of treating disorders responsive to nicotinic acetylcholine… |
| PNA-Detection of Pathogens (U.S. Patent Number 13/592,490) | The laboratory of Daniel Appella, PhD. has developed a prototype HIV testing kit that employs a peptide nucleic acid probe to capture HIV RNA recovered from patient blood. The probe targets a highly conserved segment of the Gag sequence. Initial… |
| Predicting Response to Standardized Pediatric Colitis Therapy
(PROTECT)
| The mission of the PROTECT Study is to provide a better understanding of how children newly diagnosed with ulcerative colitis (UC) respond to mesalamine and prednisone (corticosteroid), the standard initial therapies used to treat this disorder… |
| Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network
(MAPP)
| To help better understand the underlying causes of the two most prominent chronic urological pain syndromes—interstitial cystitis/painful bladder syndrome (IC/PBS) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)—the National Institute… |
| Intestinal Stem Cell Consortium
(ISCC)
| The mission of the ISCC is to advance the understanding of intestinal epithelial stem cell biology during development, homeostasis, regeneration and disease. The immediate goals of the ISCC are to isolate, characterize, culture and validate… |